Torrent Pharma Q2 profit falls 9.6% to ₹534 crore, revenue rises 51%

Torrent Pharma reported a mixed financial performance for the second quarter of fiscal 2027, with total revenue growing by 51% to ₹1,740 crore. However, the company's net profit slipped by 9.6% to ₹534 crore. This divergence was primarily driven by higher finance costs and increased depreciation expenses, which ate into the company's bottom line despite the strong sales growth.

For investors, this report highlights a scenario where operational expansion is outpacing immediate profitability. The significant jump in revenue suggests the company is successfully executing its growth strategy, but the rising costs indicate a need for operational efficiency. The focus now shifts to how management plans to manage these expenses in the coming quarters to restore profit margins.

Investors should keep a close watch on the company's future commentary regarding raw material costs and pricing power. If the current cost structure remains a drag, it could limit the upside potential of the stock. Monitoring the guidance for the upcoming quarters will be key to understanding if the company can sustain this growth trajectory while improving its earnings.